Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01986933 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

A Phase 2 study of Atopic Dermatitis, sponsored by Chugai Pharmaceutical.

Completed
Registry status
Phase 2
Development phase
264
Enrollment target
18
Study locations

NCT01986933 is a Phase 2 study of Atopic Dermatitis that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 264 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (57% lower). The trial reports 18 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01986933, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Chugai Pharmaceutical.

COMPLETED
Registry status
Phase 2
Development phase
264 participants
Enrollment target
18
Study locations

Study Summary

To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy

Conditions Studied

Atopic Dermatitis

Interventions

  • OTHER Placebo
  • DRUG nemolizumab (CIM331)

Study Locations (18)

Illinois

  • - Arlington Heights
  • - Chicago

Kentucky

  • - Louisville
  • - Louisville

South Carolina

  • - Charleston
  • - Charleston

Alabama

  • - Anniston

California

  • - San Diego

Florida

  • - Miami

Georgia

  • - Alpharetta

Indiana

  • - Indianapolis

Trial Details

FieldValue
Enrollment Target 264 participants
Start Date 2013-11
Est. Completion 2016-06
Phase Phase 2

Sponsor

Chugai Pharmaceutical

17 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01986933

The ClinicalTrials.gov registry entry for NCT01986933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (57% lower). The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01986933 reports 18 study locations spanning 15 distinct geographic areas - top geographies include Illinois, Kentucky, South Carolina.

Frequently Asked Questions

What is clinical trial NCT01986933 about?

NCT01986933 is a clinical study titled "A Phase 2 Study of CIM331 for Atopic Dermatitis Patients". To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy

What is the current status of trial NCT01986933?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2013-11. Estimated completion is 2016-06.

What conditions does trial NCT01986933 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT01986933?

The interventions under investigation include: Placebo (OTHER), nemolizumab (CIM331) (DRUG).

Who is sponsoring clinical trial NCT01986933?

This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01986933 being conducted?

This trial has 18 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.